Brief: Galderma Says Long-Term Data On Nemluvio (Nemolizumab) Demonstrate Its Favorable Safety Profile
06/06/2025 06:01
June 6 (Reuters) - GALDERMA GROUP AG GALD.S: LONG-TERM DATA ON NEMLUVIO (NEMOLIZUMAB) DEMONSTRATE ITS FAVORABLE SAFETY PROFILE LONG-TERM DATA ON NEMLUVIO (NEMOLIZUMAB) DEMONSTRATE ITS SUSTAINED AND INCREASED IMPROVEMENTS IN ITCH AND SKIN LESIONS IN PATIENTS WITH ATOPIC DERMATITIS UP TO TWO YEARS Further company coverage: GALD.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Galderma AG
See all newsBrief: Galderma Receives U.S. FDA Approval For Differin Epiduo Acne Gel Prescription-To-Otc Switch
Bayer down after 'mixed reception' at U.S Supreme Court
Europe Research Roundup: Asta Energy Solutions, Dassault Systemes, Nokia
Swiss stocks - Factors to watch on April 24
Skincare company Galderma posts 25.5% sales leap, driven by US market (updated)